A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn's Disease

Trial Profile

A Phase 3, Open-label Study to Determine the Long-Term Safety and Efficacy of Vedolizumab (MLN0002) in Patients with Ulcerative Colitis and Crohn's Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms GEMINI-LTS
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 06 Feb 2018 Status changed from active, no longer recruiting to completed.
    • 01 Feb 2018 This trial has been completed in Estonia, (End date: 2017-10-31) according to European Clinical Trials Database record.
    • 11 Jul 2017 This trial has been completed in Austria, according to European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top